Abstract Background: There are few studies dedicated to the characterization of the geriatric population with psoriasis, which has particularities in terms of clinical manifestations and therapeutic limitations. As psoriasis is a chronic disease, presenting a higher prevalence with age, the increase in life expectancy in Brazil demands knowledge about the behavior of the disease among the elderly. Objectives: To characterize elderly people with psoriasis from a tertiary service, from the clinical-epidemiological point of view, presence of comorbidities, physical frailty, and affective impact, and to compare these aspects with adults with psoriasis and elderly people without the disease. Methods: Cross-sectional study of 64 elderly patients with psoriasis, 64 adults with psoriasis, and 64 elderly patients without the disease. Clinical-demographic aspects, the Beck depression scale, and Skindex-16 were evaluated. Indicators of physical frailty were evaluated in elderly patients: handgrip, sit-to-stand test, fatigue, and weight loss >5%. Results: In the elderly, the mean age (SD) of psoriasis onset was 44 (10) years, men represented 47% of the sample, the prevalence of arthritis was 22%, and ungual involvement occurred in 72%. Topical corticosteroids were used more often among elderly people with psoriasis (100%) than among adults with the disease (86%), with no difference among other systemic treatments. Diabetes mellitus occurred in 30% of the elderly. Hypertension (59%), dyslipidemia (52%), depression (34%), and fatigue (59%) were more prevalent among the elderly with psoriasis than among the healthy controls. Background limitations Objectives service clinicalepidemiological epidemiological view comorbidities impact Methods Crosssectional Cross sectional 6 Clinicaldemographic Clinical demographic scale Skindex16 Skindex 16 Skindex-1 handgrip sittostand sit stand test 5 >5% Results SD (SD 4 10 (10 years 47 sample 22 22% 72 72% 100% 100 (100% 86%, 86 86% , (86%) treatments 30 59%, 59 59% 52%, 52 52% (52%) 34%, 34 34% (34%) (59% controls Skindex1 1 Skindex- >5 (1 2 7 (100 8 (86% 3 (52% (34% (59 > ( (86 (52 (34 (5 (8 (3

Abstract Immunobiologicals represent an innovative therapeutic option in dermatology. They are indicated in severe and refractory cases of different diseases when there is contraindication, intolerance, or failure of conventional systemic therapy and in cases with significant impairment of patient quality of life. The main immunobiologicals used in dermatology basically include inhibitors of tumor necrosis factor-alpha (anti-TNF), inhibitors of interleukin-12 and -23 (anti-IL12/23), inhibitors of interleukin-17 and its receptor (anti-IL17), inhibitors of interleukin-23 (anti-IL23), rituximab (anti-CD20 antibody), dupilumab (anti-IL4/IL13) and intravenous immunoglobulin. Their immunomodulatory action may be associated with an increase in the risk of infections in the short and long term, and each case must be assessed individually, according to the risk inherent to the drug, the patient general condition, and the need for precautions. This article will discuss the main risks of infection associated with the use of immunobiologicals, addressing the risk in immunocompetent and immunosuppressed patients, vaccination, fungal infections, tuberculosis, leprosy, and viral hepatitis, and how to manage the patient in the most diverse scenarios. contraindication intolerance life factoralpha factor alpha antiTNF, antiTNF anti TNF , (anti-TNF) interleukin12 interleukin 12 interleukin-1 23 -2 antiIL12/23, antiIL1223 antiIL IL12/23 IL12 IL (anti-IL12/23) interleukin17 17 antiIL17, antiIL17 IL17 (anti-IL17) interleukin23 interleukin-2 antiIL23, antiIL23 IL23 (anti-IL23) antiCD20 antiCD CD20 CD (anti-CD2 antibody, antibody antibody) antiIL4/IL13 antiIL4IL13 antiILIL IL4/IL13 IL4 IL13 (anti-IL4/IL13 immunoglobulin term individually drug condition precautions patients vaccination tuberculosis leprosy hepatitis scenarios (anti-TNF interleukin1 1 interleukin- 2 - antiIL12 antiIL12/23 antiIL122 IL1223 IL12/2 IL1 (anti-IL12/23 antiIL1 (anti-IL17 interleukin2 antiIL2 IL2 (anti-IL23 antiCD2 CD2 (anti-CD antiIL4 antiIL4/IL1 antiIL4IL1 IL4IL13 ILIL IL4/IL1 (anti-IL4/IL1 antiIL12/2 IL122 IL12/ (anti-IL12/2 (anti-IL1 (anti-IL2 antiIL4/IL antiIL4IL IL4IL1 IL4/IL (anti-IL4/IL antiIL12/ (anti-IL12/ (anti-IL IL4IL (anti-IL12

Abstract Background Psoriasis is a chronic inflammatory disease associated with systemic inflammation and comorbidities. Changes in the composition of the intestinal microbiome are involved in the pathogenesis of inflammatory diseases and metabolic syndrome. Characterizing the intestinal microbiome of patients with psoriasis may be relevant for the understanding of its clinical course and comorbidity prevention. Objective To characterize the intestinal microbiome of men with psoriasis compared to omnivore and vegetarian controls (without psoriasis). Method Cross-sectional study of 42 adult males: 21 omnivores with psoriasis; and controls: 14 omnivores and 7 vegetarian individuals. The characterization of the intestinal microbiome was performed by metagenomic analysis. Serum levels of lipopolysaccharide-binding protein (LPB) and C-reactive protein (CRP) were evaluated. Results The groups differed from each other regarding nutritional aspects and microbiome; individuals with psoriasis had a higher consumption of protein and lower consumption of fibers. Levels of LPB, CRP, and the Firmicutes/Bacteroidetes ratio were higher in the group with psoriasis than in the vegetarian group (p < 0.05). The genera Prevotella, Mogibacterium, Dorea, Bifidobacterium and Coprococcus, differed in the group with psoriasis compared to vegetarians; the genera Mogibacterium, Collinsella and Desulfovibrio differed from omnivores. A microbiome pattern linked to psoriasis (plsPSO) was identified, which was associated with higher LPB levels (rho = 0.39; p = 0.02), and lower dietary fiber intake (rho = −0.71; p < 0.01). Study limitations Only adult men were evaluated. Conclusion A difference was identified in the intestinal microbiome of adult men with psoriasis when compared to healthy omnivores and vegetarian controls. The identified microbiome pattern was correlated with dietary fiber intake and serum levels of LPB. comorbidities syndrome prevention without psoriasis. . psoriasis) Crosssectional Cross sectional 4 males 2 1 analysis lipopolysaccharidebinding lipopolysaccharide binding (LPB Creactive C reactive CRP (CRP evaluated fibers FirmicutesBacteroidetes Firmicutes Bacteroidetes 0.05. 005 0.05 0 05 0.05) Prevotella Mogibacterium Dorea Coprococcus vegetarians plsPSO (plsPSO rho 0.39 039 39 0.02, 002 0.02 , 02 0.02) −0.71 071 71 0.01. 001 0.01 01 0.01) 00 0.0 0.3 03 3 −0.7 07 0. −0. −0 −

Abstract Mantle cell lymphoma is an aggressive B-cell, non-Hodgkin’s lymphoma, with lymph node or extranodal origin, and a mean survival of three to five years. Skin involvement is rare, secondary and indicates neoplasia dissemination. The authors report a case of a female patient, 69 years old, diagnosed previously, after lymph node and bone marrow biopsy. She was undergoing the second chemotherapy regimen when she showed infiltrated plaque-like lesions, nodules and tumors on the trunk and thigh root. Histopathology and immunohistochemistry demonstrated cutaneous infiltration of the blastoid lymphoma.